This is a national, multi-centre, randomized, double-blind placebo-controlled, phase III
superiority trial.
The main objective of the trial is to assess the efficacy of Lcr35® by comparing the mean
time before the onset of the first clinical recurrence confirmed by laboratory tests in
patients with bacterial vaginosis treated with Lcr35® versus placebo.
Patients with bacterial vaginosis will be enroll by private gynecologists. Each patient will
receive a treatment for the initial episode(Metronidazole)and a treatment to prevent the
recurrence of bacterial vaginosis (Lcr35®).